XBiotech to Provide First Quarter 2017 Business Update
(Thomson Reuters ONE) -
AUSTIN, Texas, April 28, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT)
announced today it will host a conference call and live audio webcast
on Thursday, May 4, 2017, at 8:30 a.m. Eastern Time, to provide an overview of
its corporate and clinical activities. The call will encompass developments
during the first quarter ended March 31, 2017.
Conference Call Information:
Interested participants and investors may access the conference call by dialing:
* 1 (844) 249-9385 (U.S.)
* 1 (270) 823-1533 (International)
* Conference ID: 15848733
A live audio webcast will also be accessible via the Investors section of
the XBiotech website www.xbiotech.com. The webcast replay will remain available
for 90 days.
A telephonic replay of the conference call can be accessed by dialing 1 (855)
859-2056 (U.S.) or 1 (404) 537-3406, and providing the Conference ID:
15848733. The telephonic replay will be available for 24 hours beginning at
11:29 p.m. Eastern Time on May 4, 2017.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human(TM) proprietary technology. XBiotech
currently is advancing a robust pipeline of antibody therapies to redefine the
standards of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly, cost-
effectively and flexibly produce new therapies urgently needed by patients
worldwide.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including with respect
to the proposed offering of common shares, declarations regarding management's
beliefs and expectations that involve substantial risks and uncertainties. In
some cases, you can identify forward-looking statements by terminology such as
"may," "will," "should," "would," "could," "expects," "plans," "contemplate,"
"anticipates," "believes," "estimates," "predicts," "projects," "intend" or
"continue" or the negative of such terms or other comparable terminology,
although not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and uncertainties in
predicting future results and conditions that could cause the actual results to
differ materially from those projected in these forward-looking statements.
These risks and uncertainties are subject to the disclosures set forth in the
"Risk Factors" section of certain of our SEC filings. Forward-looking statements
are not guarantees of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the industry in which
we operate, may differ materially from the forward-looking statements contained
in this press release. Any forward-looking statements that we make in this press
release speak only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
Contact
Ashley Otero
aotero(at)xbiotech.com
512-386-2930
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 28.04.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 539090
Anzahl Zeichen: 4095
contact information:
Town:
Austin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XBiotech to Provide First Quarter 2017 Business Update"
steht unter der journalistisch-redaktionellen Verantwortung von
XBiotech, Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
